Innovator Growth Accelerated Plus ETF - October (BATS: QTOC)

Latest News for Innovator Growth Accelerated Plus ETF - October (BATS:QTOC)

Innovator Growth Accelerated Plus ETF - October

Inflation erodes the purchasing power of money over time, meaning the same amount of money today will buy fewer goods and services down the road. Consequently, saving money without considering investments or strategies to combat inflation could result in diminished value of those savings.
That's one reason real estate mogul<a href="https://www.benzinga.com/personal-finance/24/05/38763051/broke-but-brilliant-grant-cardone-says-necessity-breeds-innovation"> Grant Cardone</a> wrote, "Saving money is for losers" in a<a href="https://twitter.com/GrantCardone/status/1788240819045957840"> May 8 post on X</a>.
Cardone's calculations reveal that if you lived in New York or California in 2020 and had $1 million in a savings account earning 3%, your account would have $1.125 million in it today.
Don't Miss:
<ul>
<li>Only 0.2% of single-family rentals make this platform's rigorous cut. You can co-invest in them <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">with Jeff Bezos and other notable investors for only $100</a>.</li>
<li>Elon Musk, Ken Griffin and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US. <a href="https://www.benzinga.com/money/cityfunds-yield">Investing in its booming real estate market has never been more accessible</a>. </li>
</ul>
But if you deduct the $48,750 you'd owe in federal taxes, $12,500 in state taxes and the $281,250 "inflation effect," your total loss would be $342,500, leaving your account with a real value of $782,500.
That's a loss of 31% of the value of your savings and doesn't account for the<a href="https://www.benzinga.com/real-estate/24/05/38642088/grant-cardone-slams-bidens-tax-proposal-as-another-attempt-to-destroy-middle-class-america"> investment opportunities</a> you missed, Cardone said.
Cardone noted that, "most people's parents instructed them to "save your money," "prepare for a rainy day" and "a penny saved is a penny earned." The math suggests that saving is losing?"
"Money is being printed at record levels, Biden wants to raise taxes, threatening to take capital gains to 44%, Apple makes biggest buyback in history, Mike Saylor…converting his company's fiat to BTC [Bitcoin] and banks are in the headlines everyday for being vulnerable," Cardone wrote in the post. "What your parents told you about saving money might make ‘sense,' but the math proves saving money does not make money."
Trending:
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/real-estate/23/05/32554601/want-to-grow-your-wealth-passively-these-high-yield-real-estate-notes-might-be-your-holy-grail">These High-Yield Real Estate Notes Might Be Your Holy Grail</a> </li>
</ul>
The debate over whether to save money or invest it has gained steam since inflation began to soar and the Federal Reserve began hiking interest rates in March 2022. While high interest rates could mean increased returns on savings, experts say there are many things to consider.
"We're now in a position where you can earn decent returns on cash, and actually, now inflation is falling you can earn higher than inflation on chase," Laura Suter, head of personal finance at AJ Bell told CNBC's "Squawk Box Europe."
However, Emma Wall, head of investment analysis and research at Hargreaves Lansdown, talks in favour of Cardone's point of view. She said investing may have a bigger payoff long-term.
"Investing always outperforms cash over the longer time frames," Wall told CNBC. "Over a 30-year time horizon, history suggests that investing can be twice as powerful than leaving your money in cash."
&nbsp;Read Next:
<ul>
<li>Commercial real estate has historically outperformed the stock market, but few investors have the capital or resources needed to invest in this asset class. This platform <a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate">allows individuals to invest in commercial real estate with as little as $5,000. </a></li>
<li>This Bezos-backed startup selects America's prime single-family rentals and then <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">lets you invest in them</a> starting from $100. </li>
</ul>

Real Estate

Grant Cardone Says 'Saving Money Is For Losers'

JMP Securities analyst Jonathan Wolleben reiterates Crinetics Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) with a Market Outperform and maintains $80 price target.

News

Price Target

Reiteration

Analyst Ratings

CRNX

JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $80 Price Target

Shares of Diodes Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIOD#NASDAQ">DIOD</a>) fell sharply during Friday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/DIOD/earnings">quarterly financial results</a>.
Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Diodes shares dipped 9.8% to $68.99 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and develop COVID-influenza combination vaccines.</li>
<li>iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) gained 40% to $17.06 after the company announced a $120 million registered direct offering and reported Q1 financial results.</li>
<li>AEye, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) shares climbed 39.8% to $1.65 after the company disclosed a partnership with LITEON Technology Corporation.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) shares climbed 39.4% to $32.86 after the company reported better-than-expected first-quarter sales results.</li>
<li>Ouster, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) gained 34.3% to $13.90 after the company reported better-than-expected first-quarter financial results.</li>
<li>Organogenesis Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) rose 32% to $3.02 following upbeat quarterly results.</li>
<li>Inseego Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) gained 31.4% to $5.05 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) surged 26.3% to $13.99 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Sensus Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) shares rose 22.5% to $4.6699 after the company reported better-than-expected first-quarter financial results.</li>
<li>Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) gained 22.3% to $12.85 after the company reported better-than-expected first-quarter results.</li>
<li>Standard Lithium Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLI#NYSE">SLI</a>) jumped 21.8% to $1.90 after the company reported better-than-expected quarterly GAAP EPS results.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) rose 21% to $8.39 after the company reported better-than-expected first-quarter financial results and issued strong revenue guidance.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares gained 19.3% to $5.66 in pre-market trading after the company reported better-than-expected first quarter financial results.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) rose 17.2% to $12.79 after the company reported better-than-expected first quarter financial results. The company announced the sale of 100% of its issued and outstanding stock of Interboro Insurance Company to Forza Insurance Holdings.</li>
<li>Global Gas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGAS#NASDAQ">HGAS</a>) rose 15.3% to $1.28.</li>
<li>Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) gained 15% to $23.42 after the company reported better-than-expected quarterly earnings and authorized a $3 billion share repurchase program.</li>
<li>Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) gained 14.6% to $1,478.49 after the company reported better-than-expected first-quarter financial results and issued guidance.</li>
<li>SkyWater Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYT#NASDAQ">SKYT</a>) rose 14.4% to $7.61.</li>
<li>Clean Energy Fuels Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNE#NASDAQ">CLNE</a>) climbed 13.6% to $2.74 following upbeat quarterly results.</li>
<li>Natural Grocers by Vitamin Cottage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGVC#NASDAQ">NGVC</a>) gained 13.2% to $20.19 following second-quarter results.</li>
<li>Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) rose 11.3% to $106.36 following strong first-quarter earnings.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) jumped 11% to $6.50 following first-quarter results.</li>
<li>Integral Ad Science Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) gained 8.8% to $9.12 after the company reported better-than-expected first-quarter sales results and issued FY24 revenue guidance above estimates.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) jumped 8.7% to $35.68 after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $33 to $46.</li>
<li>Funko Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) gained 7% to $7.30 as the company reported better-than-expected first-quarter earnings and issued strong earnings forecast for the second quarter. The company also appointed Cynthia Williams as its Chief Executive Officer, effective May 20.</li>
<li>Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) gained 6.8% to $34.26 after the company reported better-than-expected first-quarter financial results and raised its FY24 EPS range.</li>
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) shares rose 3.5% to $12.94 after the company reported stronger-than-expected financial results for the first quarter on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) shares fell 73.4% to $3.9089 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) fell 37.2% to $0.0439 after jumping 20% on Thursday.</li>
<li>Flux Power Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLUX#NASDAQ">FLUX</a>) dipped 35.8% to $2.9350 after the company reported worse-than-expected quarterly financial results.</li>
<li>Antelope Enterprise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) fell 29.3% to $1.30 after the company announced second half and full year 2023 financial results.</li>
<li>Evolv Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) fell 29.2% to $2.7290 after the company reported worse-than-expected first-quarter financial results and lowered its FY24 sales guidance below estimates.</li>
<li>Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) fell 27% to $3.0950 as the company posted a loss for its first quarter on Thursday.</li>
<li>Biofrontera Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) fell 26.6% to $1.16.</li>
<li>American Vanguard Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVD#NYSE">AVD</a>) dipped 22.2% to $9.84 following weak quarterly results.</li>
<li>UTime Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) dipped 22% to $0.25.</li>
<li>The Beauty Health Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) fell 22% to $2.80 following quarterly results.</li>
<li>MicroVision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) shares fell 21.6% to $1.27 after the company reported worse-than-expected first-quarter GAAP EPS results.</li>
<li>Progyny, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) shares fell 21.5% to $25.51 after the company reported worse-than-expected first-quarter sales results and issued FY24 sales guidance below estimates.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) shares declined 20.7% to $0.0579 after the company reported worse-than-expected first quarter financial results.</li>
<li>The E.W. Scripps Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSP#NASDAQ">SSP</a>) dipped 19.7% to $3.71 following quarterly results.</li>
<li>CS Disco, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAW#NYSE">LAW</a>) fell 19.6% to $6.50 following weak sales.</li>
<li>Safe and Green Development Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGD#NASDAQ">SGD</a>) shares fell 18.4% to $0.6937 after jumping around 37% on Thursday.</li>
<li>Docebo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) fell 18.2% to $37.99.</li>
<li>JFrog Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) shares fell 17.7% to $33.43 after the company reported first quarter financial results.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) shares fell 17.3% to $0.7606 after the company reported worse-than-expected first-quarter sales results.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) fell 15.6% to $11.35 following first-quarter financial results.</li>
<li>Gritstone bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares declined 14.4% to $0.8320 after the company reported worse-than-expected first quarter GAAP EPS results.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) shares fell 12.8% to $4.0850 after the company reported worse-than-expected first-quarter adjusted EPS results.</li>
<li>Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) declined 12.2% to $14.72.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) fell 11.1% to $21.97 after the company reported second-quarter financial results.</li>
<li>AMN Healthcare Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) fell 9.5% to $55.08 following first-quarter results.</li>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) fell 8.4% to $24.69 after the company reported first-quarter financial results.</li>
<li>Akamai Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) fell 8.1% to $94.16 after the company issued weak guidance.</li>
<li>Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) declined 7.8% to $17.28 following second-quarter financial results.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) dipped 7.4% to $3.3399.</li>
<li>MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) fell 7% to $39.02.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) fell 5% to $33.13. BMO Capital analyst James Fotheringham maintained Affirm with a Market Perform and lowered the price target from $48 to $46.</li>
<li>Runway Growth Finance Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWAY#NASDAQ">RWAY</a>) shares fell 4.1% to $11.61 as the company priced its secondary offering of 3.75 million common stock by selling stockholder at $11.50 per share.</li>
<li>Yelp Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) shares declined 3.6% to $38.20 after the company reported a first-quarter revenue miss.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38760794/bitcoin-tops-63-000-akash-network-emerges-as-top-gainer">Bitcoin Tops $63,000; Akash Network Emerges As Top Gainer</a>

Intraday Update

Movers

ACIC

ADMA

AEHL

AFRM

AKAM

ARRY

ARWR

BFRI

BROS

CDNA

CLNE

DCBO

DIOD

EVLV

FLNC

FLUX

FNKO

FROG

FWRD

GRPN

GRTS

GWAV

HGAS

INSG

IOVA

ITOS

LIDR

MGNX

MLTX

MVIS

NGVC

NTRA

NVAX

NVTS

ORGO

OUST

PEGY

PGNY

RVNC

RWAY

SKIN

SKYT

SOUN

SRTS

YELP

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Northland Capital Markets analyst Ted Jackson downgrades Hyster-Yale Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) from Outperform to Market Perform and raises the price target from $80 to $90.

Downgrades

Northland Capital Markets Downgrades Hyster-Yale Materials to Market Perform, Raises Price Target to $90

JMP Securities analyst Jason Butler maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Market Outperform and lowers the price target from $471 to $468.

ARGX

JMP Securities Maintains Market Outperform on argenx, Lowers Price Target to $468

MoffettNathanson analyst Clay Griffin upgrades Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) from Sell to Neutral and lowers the price target from $31 to $26.

Upgrades

RBLX

MoffettNathanson Upgrades Roblox to Neutral, Lowers Price Target to $26

WIIM

Cue Biopharma shares are trading lower. The company reported Q1 financial results.

JMP Securities analyst Constantine Davides reiterates AMN Healthcare Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) with a Market Outperform and maintains $75 price target.

JMP Securities Reiterates Market Outperform on AMN Healthcare Services, Maintains $75 Price Target

<a href="https://patentcenter.uspto.gov/applications/17273159/ifw/docs">Patent Center (uspto.gov)</a>
<figure class="image"><img src="https://pbs.twimg.com/media/GNOwbQPaIAAMlkw?format=jpg&amp;name=small" alt="Image" /></figure><figure class="image"><img src="https://pbs.twimg.com/media/GNOwbQSacAAiMWx?format=jpg&amp;name=small" alt="Image" /></figure>
&nbsp;

Biotech

General

YTEN

Yield10 Bioscience Has Received A Notice Of Allowance For Its U.S. Patent Application 17/273,159 Titled "Genetically Engineered Land Plants That Express An Increased Seed Yield Protein And/Or An Increased Seed Yield RNA".

Evercore ISI Group analyst Mark Lipacis maintains Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) with a Outperform and raises the price target from $235 to $250.

ONTO

Evercore ISI Group Maintains Outperform on Onto Innovation, Raises Price Target to $250

Deutsche Bank analyst Corinne Blanchard maintains SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) with a Hold and lowers the price target from $75 to $55.

SEDG

Deutsche Bank Maintains Hold on SolarEdge Technologies, Lowers Price Target to $55

EGAN

eGain shares are trading lower after the company reported mixed Q3 financial results.

Mizuho&nbsp;analyst Siti Panigrahi upgraded&nbsp;Squarespace&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQSP#NYSE">SQSP</a>) to Buy from Neutral,<a target="_blank" href="https://www.benzinga.com/quote/SQSP/analyst-ratings" rel="noreferrer noopener">&nbsp;raising the forecast to $50 from $34.</a>
According to the analyst, the company can deliver a&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">significant upside to consensus estimates</a>. The upside scenario implies almost 22% year-over-year growth in 2024 (consensus at 19%). Squarespace&nbsp;also has potential for 20% year-over-year&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">growth in 2025 (consensus at 14%).</a>
The major growth levers underappreciated for Squarespace&nbsp;are &#8211; Google Domains asset acquisition and its halo effect driving new domains, pricing tailwind in 2025, and a modest contribution from Squarespace Payments.&nbsp;
Panigrahi&nbsp;emphasizes that these drivers will position the company for 20%+ growth with 30% uFCF margins over the medium term.
The Google Domains acquisition has already contributed $13 million of revenue in the first quarter alone.
In addition, management noted that Squarespace is seeing &#8220;greatly increased traffic&#8221; in new domains coming onto the platform due to the halo effect from the acquisition, with Google directing users directly to Squarespace for their domain needs, Panigrahi&nbsp;says.
The analyst estimates that the domains could contribute $93 million in revenue in 2024 and $153 million in 2025.
Panigrahi added that a pricing increase for Squarespace could generate a $35 million incremental revenue tailwind in 2025.
Squarespace recognizes payment revenues on a net basis&nbsp;and&nbsp;Payments could generate a modest $6 million revenue contribution in 2025.&nbsp;
The investor day next week could&nbsp;be a catalyst for shares to re-rate, the analyst notes.&nbsp;
After Squarespace&#8217;s first quarter earnings&nbsp;reported&nbsp;earlier this week, the analyst raised FY24 revenue and uFCF estimates to $1.202 billion (19% Y/Y) and $307 million from $1.184 billion (17% Y/Y) and $296 million previously.
Price Action: SQSP shares are trading higher by 3.48% to $38.13 at last check Friday.
Photo via Shutterstock

Analyst Color

Equities

Markets

Trading Ideas

SQSP

Squarespace To See Whopping 20% Growth Over Medium Term On Pricing Tailwinds: Analyst

Deutsche Bank analyst Steve Powers maintains Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) with a Hold and raises the price target from $85 to $91.

Deutsche Bank Maintains Hold on Spectrum Brands Holdings, Raises Price Target to $91

JMP Securities analyst Jonathan Wolleben maintains Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Market Outperform and lowers the price target from $25 to $24.

JMP Securities Maintains Market Outperform on Altimmune, Lowers Price Target to $24

Deutsche Bank analyst Steve Powers maintains Primo Water (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRMW#NYSE">PRMW</a>) with a Hold and raises the price target from $17 to $20.

PRMW

Deutsche Bank Maintains Hold on Primo Water, Raises Price Target to $20

Deutsche Bank analyst Lauren Silberman maintains Papa John's International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>) with a Hold and lowers the price target from $77 to $58.

PZZA

Deutsche Bank Maintains Hold on Papa John's International, Lowers Price Target to $58

Whales with a lot of money to spend have taken a noticeably bearish stance on Iovance Biotherapeutics.
Looking at options history for Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) we detected 17 trades.
If we consider the specifics of each trade, it is accurate to state that 17% of the investors opened trades with bullish expectations and 82% with bearish.
From the overall spotted trades, 12 are puts, for a total amount of $589,675 and 5, calls, for a total amount of $608,250.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $10.0 and $15.0 for Iovance Biotherapeutics, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Iovance Biotherapeutics stands at 1138.5, with a total volume reaching 11,833.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Iovance Biotherapeutics, situated within the strike price corridor from $10.0 to $15.0, throughout the last 30 days.
<h3>Iovance Biotherapeutics Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715358762_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.55</td>
<td>$2.45</td>
<td>$2.45</td>
<td>$14.00</td>
<td>$220.5K</td>
<td>8</td>
<td style="text-align: right;">602</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.55</td>
<td>$2.4</td>
<td>$2.4</td>
<td>$14.00</td>
<td>$144.0K</td>
<td>8</td>
<td style="text-align: right;">602</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$2.5</td>
<td>$2.3</td>
<td>$2.5</td>
<td>$10.00</td>
<td>$125.0K</td>
<td>3.0K</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>IOVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$4.2</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$15.00</td>
<td>$78.8K</td>
<td>578</td>
<td style="text-align: right;">197</td>
</tr>
<tr>
<td>IOVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$1.55</td>
<td>$1.4</td>
<td>$1.55</td>
<td>$10.00</td>
<td>$74.7K</td>
<td>854</td>
<td style="text-align: right;">231</td>
</tr>
</tbody>
</table>

<h3>About Iovance Biotherapeutics</h3>
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
In light of the recent options history for Iovance Biotherapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Iovance Biotherapeutics Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 11,609,305, the IOVA's price is down by -17.77%, now at $11.06. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 88 days.</li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Iovance Biotherapeutics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Iovance Biotherapeutics's Options: A Look at What the Big Money is Thinking

Whales with a lot of money to spend have taken a noticeably bullish stance on Fair Isaac.
Looking at options history for Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 12% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $615,625 and 3, calls, for a total amount of $119,300.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $1000.0 to $1320.0 for Fair Isaac over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Fair Isaac stands at 27.33, with a total volume reaching 72.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Fair Isaac, situated within the strike price corridor from $1000.0 to $1320.0, throughout the last 30 days.
<h3>Fair Isaac Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715358756_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FICO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$54.9</td>
<td>$53.3</td>
<td>$53.3</td>
<td>$1150.00</td>
<td>$298.4K</td>
<td style="text-align: right;">88</td>
<td style="text-align: right;">56</td>
</tr>
<tr>
<td>FICO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$95.4</td>
<td>$88.0</td>
<td>$92.4</td>
<td>$1320.00</td>
<td>$120.1K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>FICO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$80.9</td>
<td>$75.8</td>
<td>$76.9</td>
<td>$1290.00</td>
<td>$92.2K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>FICO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$48.3</td>
<td>$43.3</td>
<td>$48.2</td>
<td>$1200.00</td>
<td>$57.8K</td>
<td style="text-align: right;">56</td>
<td style="text-align: right;">12</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$108.8</td>
<td>$104.6</td>
<td>$104.6</td>
<td>$1280.00</td>
<td>$52.3K</td>
<td style="text-align: right;">13</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>

<h3>About Fair Isaac</h3>
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's credit scores business accounts for most of the firm's profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
In light of the recent options history for Fair Isaac, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Fair Isaac's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 205,451, the FICO's price is up by 5.18%, now at $1353.46. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 82 days.</li>
</ul>
<h3>What Analysts Are Saying About Fair Isaac</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $1382.75.
<ul>
<li>An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $1500. </li>
<li>Reflecting concerns, an analyst from Redburn Atlantic lowers its rating to Neutral with a new price target of $1113.</li>
<li>In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $1500. </li>
<li>An analyst from Raymond James persists with their Outperform rating on Fair Isaac, maintaining a target price of $1418. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Fair Isaac options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

FICO

Market Whales and Their Recent Bets on FICO Options

Financial giants have made a conspicuous bearish move on NexGen Energy. Our analysis of options history for NexGen Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) revealed 18 unusual trades.
Delving into the details, we found 38% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $763,280, and 13 were calls, valued at $582,196.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $7.0 to $10.0 for NexGen Energy during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of NexGen Energy stands at 14921.67, with a total volume reaching 71,293.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in NexGen Energy, situated within the strike price corridor from $7.0 to $10.0, throughout the last 30 days.
<h3>NexGen Energy Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715358751_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NXE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$0.2</td>
<td>$0.15</td>
<td>$0.18</td>
<td>$7.00</td>
<td>$540.0K</td>
<td>1.9K</td>
<td>60.1K</td>
</tr>
<tr>
<td>NXE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$2.15</td>
<td>$2.05</td>
<td>$2.15</td>
<td>$9.00</td>
<td>$104.4K</td>
<td>312</td>
<td>486</td>
</tr>
<tr>
<td>NXE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$1.05</td>
<td>$0.95</td>
<td>$0.96</td>
<td>$8.00</td>
<td>$97.9K</td>
<td>2.7K</td>
<td>0</td>
</tr>
<tr>
<td>NXE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$1.05</td>
<td>$0.95</td>
<td>$0.97</td>
<td>$8.00</td>
<td>$97.0K</td>
<td>2.7K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NXE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$1.1</td>
<td>$1.0</td>
<td>$1.1</td>
<td>$10.00</td>
<td>$79.9K</td>
<td>100.9K</td>
<td>293</td>
</tr>
</tbody>
</table>

<h3>About NexGen Energy</h3>
NexGen Energy Ltd is a mineral exploration company. It is engaged in the acquisition, exploration, evaluation and development of uranium properties in Canada. The company's projects portfolio consists of ROOK I, and the IsoEnergy, at the Athabasca Basin. The Rook I property hosts the world-class Arrow Zone, the Bow discovery. as well as the discovered Harpoon area located northeast of the Arrow deposit.
In light of the recent options history for NexGen Energy, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of NexGen Energy</h3>
<ul>
<li>With a volume of 5,565,254, the price of NXE is down -9.19% at $7.31. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 89 days.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for NexGen Energy, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Nuveen Arizona Dividend Advantage Municipal Funds 3

Check Out What Whales Are Doing With NXE